GlassScriptPhysician profile
Michele Young
NPI 1306963046
$1,764.24
in general payments reported to CMS, 2019-2025
23 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.09 · 2022: $276 · 2023: $678 · 2024: $202 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.15 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $263.10 | 2022-2025 | |
| Abbvie INC. | $243.83 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.44 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $180.89 | 2023-2025 | |
| Incyte Corporation | $134.26 | 2025 | Jakafi |
| Puma Biotechnology, INC. | $122.69 | 2022-2023 | |
| Kite Pharma, INC. | $121.13 | 2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $63.16 | 2021-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $60.67 | 2022-2025 | Carvykti, Tecvayli, Talvey |
| Csl Behring | $36.28 | 2022-2023 | Afstyla, Idelvion |
| Takeda Pharmaceuticals U.S.A., INC. | $34.15 | 2024 | Fruzaqla |
| Lilly USA, LLC | $33.87 | 2021-2022 | |
| Glaxosmithkline, LLC. | $30.48 | 2025 | Blenrep, Ojjaara |
| Tersera Therapeutics LLC | $29.88 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $25.20 | 2025 | Keytruda |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.52 | 2023 | |
| Sumitomo Pharma America, INC. | $23.11 | 2025 | Orgovyx |
| Array Biopharma INC | $21.52 | 2025 | Tukysa, Mektovi, Braftovi |
| Astellas Pharma US INC | $19.60 | 2025 | Padcev |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2021 | |
| Emd Serono, INC. | $14.66 | 2023 | Bavencio |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.